Black Diamond Therapeutics, Inc. (BDTX) Revenue History
Annual and quarterly revenue from 2017 to present
BDTX Revenue Over Time (2017–2025)
BDTX Revenue Growth History
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | -100.0% |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $70.0M | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
BDTX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
BDTX Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 20, 2026, Black Diamond Therapeutics, Inc. (BDTX) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
BDTX's historical revenue data shows various trends over time. Black Diamond Therapeutics, Inc.'s highest annual revenue of $70.0 million was recorded in 2025, an all-time high.
Revenue by Segment
BDTX's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including KYMR (-12.6% YoY), AUPH (+20.6% YoY), and ARVN (-79.1% YoY) — BDTX has underperformed the peer group in revenue growth. Compare BDTX vs KYMR →
BDTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BDTXCurrent | $0 | -100.0% | - | 28.4% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 AUPH | $283M | +20.6% | +41.4% | 37.1% | |
 ARVN | $263M | -79.1% | +58.9% | -43.8% |
BDTX Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $70.0M | - | $69.7M | 99.5% | $19.9M | 28.4% |
| 2024 | $0 | - | $0 | - | $-78,781,000 | - |
| 2023 | $0 | - | $-437,000 | - | $-86,460,000 | - |
| 2022 | $0 | - | $0 | - | $-92,828,000 | - |
| 2021 | $0 | - | $0 | - | $-126,872,000 | - |
| 2020 | $0 | - | $0 | - | $-69,570,000 | - |
| 2019 | $0 | - | $-47,000 | - | $-8,904,000 | - |
| 2018 | $0 | - | $-44,000 | - | $-8,904,000 | - |
| 2017 | $0 | - | $-24,000 | - | $-4,119,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BDTX — Frequently Asked Questions
Quick answers to the most common questions about buying BDTX stock.
Is BDTX's revenue growth accelerating or slowing?
BDTX revenue is declining -100.0% year-over-year. TTM revenue fell to $0.00, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is BDTX's revenue history from 2017 to 2026?
Black Diamond Therapeutics, Inc. (BDTX) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $0.00, growing at -100.0% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is BDTX's long-term revenue growth rate (CAGR)?
Black Diamond Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -100.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for BDTX.
Why does BDTX's quarterly revenue fluctuate?
BDTX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Black Diamond Therapeutics, Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is BDTX's revenue distributed by segment?
BDTX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does BDTX's revenue compare to industry peers?
Black Diamond Therapeutics, Inc. (BDTX) with TTM revenue of $0.00 and -100.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.